Navigation Links
ChartTrends(R): Bone and Mineral Metabolism in Dialysis Reveals Latest Trends in the Treatment of Calcium, Phosphorus and PTH
Date:4/30/2009

EXTON, Pa., April 30 /PRNewswire/ -- BioTrends Research Group, Inc. released ChartTrends(R): Bone and Mineral Metabolism in Dialysis, a syndicated publication offering comprehensive insight into the management of calcium, phosphorus and PTH in dialysis patients. The report is based on actual patient and laboratory data collected in February 2009 from approximately 1,000 dialysis patient charts.

This ChartTrends(R) report sheds light on patient demographics, laboratory values, and treatment prevalence with phosphate binders, Nutritional Vitamin D, Active Vitamin D and Sensipar. Moreover, it provides information on the interplay between these therapies and uncovers actual (as opposed to self-reported) product dosing and titration, brand switching and reasons for switching, as well as brand persistency.

In the treatment of hyperphosphatemia, patients tend to be initiated on phosphate binder monotherapy when phosphorus reaches 5.7 mg/dL. Phosphorus levels are significantly higher when combination therapy is initiated. Contrary to what Nephrologists perceive based on self-reported data, combination binder therapy is prescribed infrequently. Genzyme's sevelamer is the market share leader despite the fact that it has the highest pill burden. Shire's Fosrenol has the lowest pill burden, but significantly lower persistency compared to Renagel, Tums and FMC's PhosLo. Within the sevelamer franchise, patient conversion to Renvela stands at about 27% and about half of the Renvela patients had been switched from Renagel.

The vast majority of dialysis patients are on Active Vitamin D formulations such as Abbott's Zemplar and Genzyme's Hectorol. The use of Nutritional Vitamin D (i.e. ergocalciferol) appears to be increasing and the concomitant use of Nutritional Vitamin D does have an impact on the dose of Active Vitamin D. Although the use of Active Vitamin D is widespread, a substantial number of patients are still above the target level for iPTH.

Amgen's Sensipar tends to be reserved for difficult to control patients and is initiated at a mean iPTH of 669 pg/mL, with more than one-quarter of patients being initiated when iPTH >750 pg/mL. Although MD perception is that treatment with Sensipar can result in lower doses of Vitamin D and phosphate binders, the converse is actually true. Patients treated with Sensipar tend to be on higher doses of both agents. Despite more aggressive therapy, a significant proportion of these patients remain uncontrolled.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. New property found in ancient mineral lodestone
2. Study Finds Widespread Vitamin and Mineral Use Among Cancer Survivors, Although Benefits of Such Use Remain Unclear
3. New insight to demineralization
4. Sea urchin yields a key secret of biomineralization
5. South Africas Minister of Minerals and Energy Welcomes Denham Capital Investment in BioTherm Energy to Develop Power Generation Business
6. deCODE Discovers Common Genetic Variations Contributing to Low Bone Mineral Density and Risk of Osteoporosis
7. AIM Pharmakon (API) Announced a New Proprietary Premium-Quality Natural Concentrated Liquid Calcium and Mineral Supplement Now Available Direct to Consumers
8. Free DXA Bone Mineral Density and Body Composition in Clinical Trials Webinars to be Held by M2S DXA Division Expert
9. Free DXA Bone Mineral Density and Body Composition in Clinical Trials Webinars to be Held by M2S DXA Division Expert
10. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
11. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Alex,s Lemonade Stand Foundation ... that it will open a state-of-the-art bioinformatics lab, using ... research. This announcement comes as Liz Scott , ... National Cancer Moonshot Summit in Washington, D.C. ... as a participant and advocate of pediatric cancer research ...
(Date:6/27/2016)... , June 27, 2016  Global demand for ... percent through 2020 to $7.2 billion.  This market ... beverages, cleaning products, biofuel production, animal feed, and ... diagnostics, and biocatalysts). Food and beverages will remain ... by increasing consumption of products containing enzymes in ...
(Date:6/27/2016)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") announces ... Clean Technology Fund I, LP and Clean Technology Fund ... venture capital funds which together hold approximately 59% of ... as converted basis), that they have entered into an ... in Biorem to TUS Holdings Co. Ltd. ("TUS") (en.tusholdings.com) ...
(Date:6/27/2016)... 27, 2016  Sequenom, Inc. (NASDAQ: SQNM ... lives through the development of innovative products and services, ... the United States denied its petition to ... of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") are ... by the Supreme Court,s Mayo Collaborative Services v. Prometheus ...
Breaking Biology Technology:
(Date:6/27/2016)... Research and Markets has announced the addition of the ... The report forecasts the biometrics ... a CAGR of 12.28% during the period 2016-2020. ... with inputs from industry experts. The report covers the market landscape ... includes a discussion of the key vendors operating in this market. ...
(Date:6/22/2016)... American College of Medical Genetics and Genomics was once again ... of the fastest-growing trade shows during the Fastest 50 Awards ... Las Vegas . Winners are ... of the following categories: net square feet of paid exhibit ... 2015 ACMG Annual Meeting was ranked 23 out of 50 ...
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
Breaking Biology News(10 mins):